SERVICE HOMEPAGESERVICE HOMEPAGE
Strategic Analysis of World Drug Discovery Spending
Deliverable Type: Market Research
Date Published: 12 Dec 2003
FEATURES OF THE RESEARCH VIEW BROCHUREVIEW BROCHURE  
Research Overview Research Overview Analyst Presentation Analyst Presentation
Benefits of this Service Benefits of this Service More Information More Information
Research Overview

Slow Growth of Pharmaceuticals Market Significantly Affects R&D Spending

The most pervasive reason for the slowdown in drug discovery spending is the sluggish growth of virtually every segment that contributes to product purchasing. The top 20 pharmaceutical companies dedicated $39.3 billion to R&D spending in 2002, of which 32 percent was spent on pre-clinical development. This translated into R&D product purchases of approximately $6.6 billion. As pharmaceutical top line grows at 5 to 6 percent, R&D expenditure is not expected to increase at more than 6 percent.

"Drug discovery spending is driven by three major forces: the pharmaceutical industry's need to continue to produce novel therapeutics, the biotech industry's need for continued R&D, and academic/government research," says the analyst of this research service. Advanced study and development of pharmaceuticals and therapeutics requires a significant expenditure. The R&D spending is not solely dedicated to product purchases as overheads and the payroll represent significant expenses.

In 2002, global drug discovery spending was estimated at $19.6 billion. This number is expected to reach $25.1 billion by 2006, at a compound annual growth rate of 6.3 percent. The National Institutes of Health's (NIH) budget is the single largest contributor to research product sales. Market growth will be significantly affected by a substantial decrease in the growth rate of the NIH budget, as well as a slowing of pharmaceutical and biotech R&D spending.

Frost & Sullivan Growth Partnership Service

Based on extensive and in-depth research, real-world consulting work, and new theories tested in hundreds of companies across many industries, Frost & Sullivan has evolved its Growth Partnership Services (GPS) program that provides established and emerging firms with powerful growth visions. Moving beyond token mission statements, GPS provides an actionable vision to growth consulting partners by illustrating how key intelligence and strategic research based on defined goals can guide day-to-day behavior and overall company direction. The foundation of Frost & Sullivan's GPS includes:

  • Assisting companies to reach their full potential in the core business
  • Providing growth strategies to help companies expand into related businesses
  • Preemptively redefining the core business during market turbulence
  • Applying the Frost & Sullivan framework to identify and address common mistakes resulting from misaligned corporate strategies
  • Recommending growth management strategies through continuous partnership

To maximize the potential for growth within a firm's internal and external environment, Frost & Sullivan consultants can facilitate the creation of strategic programs that deliver improved market success. Frost & Sullivan's strengths lie in combining strategic understanding with market expertise and applying these with absolute commitment to its clients' growth.

/
BACK TO TOP BACK TO TOP

QUICK SEARCH

GOGO
ADVANCED SEARCH
Search our research by date, market, technology, region or keywords
GO GO
SHARE
Discover how we can help your business
GO  GO
Learn how we can provide data and insight for your specific requirements
GO  GO
HELP DESK
For general assistance and enquiries:
Africa:
+27 21 680 3260
enquiries@frost.com

Asia Pacific:
+65 68900999
apacfrost@frost.com

Europe:
+44 (0)20 7343 8383
enquiries@frost.com

Israel:
+972-9-9502888
Israel@frost.com

Latin America:
+54 11 4777 1550
myfrost@frost.com

Middle East & North Africa:
+971.4.4331.893
meenquiries@frost.com

North America:
+1.877.463.7678
myfrost@frost.com

South Asia:
+91 (0) 22 6160 6666
saenquiries@frost.com

For a full list of our offices click here
Sitemap | Disclaimer | Privacy
© Frost & Sullivan
Conseq